At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 183 enrolled
Drug / intervention
MCI-196 +1 moredrug
Likely dose
MCI-196 500mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Study of MCI-196 for Treatment of Type 2 Diabetes in Randomized, Double-Blind, Parallel-Assignment, Placebo-Controlled Manner
In Brief
A Phase 2 clinical trial evaluating MCI-196 and Placebo of MCI-196 Tablet for Type 2 Diabetes. Completed, enrolled 183 participants.
Detailed Summary
The objective of this study is to evaluate the efficacy of MCI-196 in patients with Type 2 Diabetes based on the changes in blood glucose-related parameters and safety after 12 weeks administration in double-blind, placebo-controlled manner. And in addition, the changes in lipid-related parameters are examined.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
First PostedJul 2007
Study CompletionSep 2007
TodayJul 2026
First PostedJul 6, 2007
Enrollment StartOct 1, 2005
Study CompletionSep 1, 2007
TodayJul 2, 2026
Posted 19.0 years ago
Interventions
MCI-196drug
Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
Placebo of MCI-196 Tabletdrug
Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration